Zydus Lifesciences Limited
NSE: ZYDUSLIFE BSE: ZYDUSLIFE
NSE
995.15
0.30 (0.03%)
Prev Close
994.85
Open Price
998
Volume
775,382
Today Low / High
989.1 / 1000.2
52 WK Low / High
795 / 1324.3
Range
945 - 1,045
BSE
995.05
0.30 (0.03%)
Prev Close
994.75
Open Price
999.25
Volume
19,462
Today Low / High
989.6 / 999.95
52 WK Low / High
797.05 / 1323.9
Range
945 - 1,045
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 995.15 (target range: 945 - 1,045), reflecting a change of 0.3 (0.0301553%). On the BSE, it is listed at 995.05 (target range: 945 - 1,045), showing a change of 0.3 (0.03015833%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
30 Jul
998.00
-0.29%
29 Jul
985.00
1.00%
28 Jul
976.40
0.38%
25 Jul
967.20
0.95%
24 Jul
962.95
0.86%
23 Jul
957.70
0.44%
22 Jul
970.00
-1.37%
21 Jul
974.00
-0.41%
18 Jul
986.95
-1.22%
17 Jul
975.50
0.74%
16 Jul
980.00
-1.13%
15 Jul
971.00
-0.35%
14 Jul
982.05
-1.38%
11 Jul
973.00
0.68%
10 Jul
978.45
-0.56%
09 Jul
973.40
0.52%
08 Jul
998.80
-1.56%
07 Jul
1,001.00
-0.22%
04 Jul
1,004.00
-0.30%
03 Jul
992.05
0.74%
02 Jul
1,005.70
-1.02%
Zydus Lifesciences Limited Graph
Zydus Lifesciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Zydus Lifesciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 995.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 995.05 | 1,005.00 | 904.50 - 1,105.50 |
| 1,014.95 | 811.96 - 1,217.94 | ||
| 1,024.90 | 717.43 - 1,332.37 | ||
| Bearish Scenario | 995.05 | 985.10 | 886.59 - 1,083.61 |
| 975.15 | 780.12 - 1,170.18 | ||
| 965.20 | 675.64 - 1,254.76 |
Overview of Zydus Lifesciences Limited
ISIN
INE010B01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
980,617
Market Cap
1,001,349,784,500
Last Dividend
11
Official Website
IPO Date
2002-07-01
DCF Diff
-1,117.73
DCF
2,114
Financial Ratios Every Investor Needs
Stock Dividend of ZYDUSLIFE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 11 | 11 | 2025-07-25 | 2025-08-14 | |
| 2024-07-26 | July 26, 24 | 3 | 3 | 2024-07-26 | 2024-09-08 | |
| 2023-07-27 | July 27, 23 | 6 | 6 | 2023-07-28 | 2023-09-10 | |
| 2022-07-28 | July 28, 22 | 2.5 | 2.5 | 2022-07-29 | 2022-08-16 | |
| 2021-07-28 | July 28, 21 | 3.5 | 3.5 | 2021-07-29 | 2021-09-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 23,241.50 Cr | 6,338.00 Cr | 16,903.50 Cr | 0.7273 | 0.00 Cr | 0.00 Cr | 13,222.90 Cr | 4,525.50 Cr | 44.97 | 6,895.10 Cr | 0.1947 |
| 2024-03-31 | 19,547.40 Cr | 10,622.50 Cr | 8,924.90 Cr | 0.4566 | 1,312.50 Cr | 517.60 Cr | 4,539.50 Cr | 3,859.50 Cr | 38.14 | 5,622.20 Cr | 0.1974 |
| 2023-03-31 | 16,877.80 Cr | 6,310.10 Cr | 10,567.70 Cr | 0.6261 | 135.80 Cr | 582.90 Cr | 2,852.80 Cr | 1,960.30 Cr | 19.30 | 3,442.20 Cr | 0.1161 |
| 2022-03-31 | 14,827.60 Cr | 5,818.90 Cr | 9,008.70 Cr | 0.6076 | 114.60 Cr | 428.10 Cr | 2,474.10 Cr | 4,487.30 Cr | 17.65 | 3,671.00 Cr | 0.3026 |
| 2021-03-31 | 14,821.50 Cr | 5,480.00 Cr | 9,341.50 Cr | 0.6303 | 118.40 Cr | 472.10 Cr | 2,735.60 Cr | 2,133.60 Cr | 20.84 | 3,232.90 Cr | 0.1440 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,956.80 Cr | 37,201.70 Cr | 10,843.30 Cr | 23,953.1000 Cr | 3,213.20 Cr | 256.40 Cr | 3,944.00 Cr | 7,359.90 Cr | 0.00 Cr | 0.00 Cr | 1,556.70 Cr | 9,041.6000 Cr |
| 2024-03-31 | 413.00 Cr | 29,280.80 Cr | 7,179.20 Cr | 19,829.5000 Cr | 804.20 Cr | 391.20 Cr | 3,441.90 Cr | 6,914.80 Cr | 0.00 Cr | 0.00 Cr | 11.20 Cr | 5,341.9000 Cr |
| 2023-03-31 | 487.80 Cr | 25,756.40 Cr | 6,068.10 Cr | 17,515.8000 Cr | 1,194.90 Cr | 707.10 Cr | 3,413.30 Cr | 6,826.70 Cr | 1,960.10 Cr | 29.50 Cr | 927.30 Cr | 5,530.7000 Cr |
| 2022-03-31 | 657.80 Cr | 27,795.40 Cr | 8,741.60 Cr | 16,999.6000 Cr | 4,220.90 Cr | 3,563.10 Cr | 3,719.40 Cr | 6,422.60 Cr | 1,824.40 Cr | 28.70 Cr | 934.80 Cr | 7,839.4000 Cr |
| 2021-03-31 | 665.20 Cr | 23,884.70 Cr | 8,955.10 Cr | 12,992.3000 Cr | 4,607.60 Cr | 3,942.40 Cr | 3,236.20 Cr | 6,333.20 Cr | 1,648.30 Cr | 22.70 Cr | 631.20 Cr | 7,861.3000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,776.7000 Cr | -8,372.3000 Cr | 2,014.2000 Cr | 5,064.1000 Cr | 413.8000 Cr | 826.8000 Cr | -1,712.6000 Cr | 4,525.5000 Cr | 4.2000 Cr | -302.5000 Cr | -444.9000 Cr |
| 2024-03-31 | 3,227.9000 Cr | -1,475.2000 Cr | -1,810.4000 Cr | 2,321.3000 Cr | -74.8000 Cr | 413.0000 Cr | -906.6000 Cr | 3,859.5000 Cr | -392.9000 Cr | -621.0000 Cr | -2.0000 Cr |
| 2023-03-31 | 2,688.8000 Cr | 1,171.2000 Cr | -4,400.4000 Cr | 1,657.9000 Cr | -533.8000 Cr | 573.1000 Cr | -1,030.9000 Cr | 2,582.7000 Cr | -3,147.2000 Cr | -267.1000 Cr | 440.7000 Cr |
| 2022-03-31 | 2,104.1000 Cr | 1,154.4000 Cr | -868.3000 Cr | 901.5000 Cr | 2,372.9000 Cr | 3,460.1000 Cr | -1,202.6000 Cr | 5,232.3000 Cr | -383.7000 Cr | -372.2000 Cr | -525.5000 Cr |
| 2021-03-31 | 3,293.0000 Cr | -722.5000 Cr | -2,548.9000 Cr | 2,439.0000 Cr | -90.5000 Cr | 1,087.2000 Cr | -854.0000 Cr | 2,284.8000 Cr | -3,342.7000 Cr | -1.5000 Cr | -479.7000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6,527.90 Cr | 1,697.10 Cr | 4,830.80 Cr | 0.7400 | 3,859.40 Cr | 1,170.90 Cr | 11.64 | 2,155.95 Cr | 0.1794 |
| 2024-12-31 | 5,123.50 Cr | 1,583.40 Cr | 3,540.10 Cr | 0.6910 | 976.00 Cr | 1,023.50 Cr | 10.17 | 1,445.10 Cr | 0.1998 |
| 2024-09-30 | 5,113.60 Cr | 1,471.40 Cr | 3,642.20 Cr | 0.7123 | 1,182.40 Cr | 911.20 Cr | 9.06 | 1,529.60 Cr | 0.1782 |
| 2024-06-30 | 6,207.50 Cr | 2,684.90 Cr | 3,522.60 Cr | 0.5675 | 1,893.90 Cr | 1,419.90 Cr | 14.11 | 2,147.20 Cr | 0.2287 |
| 2024-03-31 | 5,366.40 Cr | 1,611.50 Cr | 3,754.90 Cr | 0.6997 | 1,581.60 Cr | 1,182.30 Cr | 11.45 | 1,786.90 Cr | 0.2203 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,956.80 Cr | 4,851.10 Cr | 7,807.90 Cr | 4,024.70 Cr | 3,944.00 Cr | 17,046.10 Cr | 7,359.90 Cr | 37,201.70 Cr | 10,843.30 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,495.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -24,154.60 Cr |
| 2024-09-30 | 1,061.40 Cr | 1,933.70 Cr | 2,995.10 Cr | 0.00 Cr | 3,716.90 Cr | 12,156.90 Cr | 7,153.10 Cr | 31,445.90 Cr | 7,291.30 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 1,357.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -22,101.60 Cr |
| 2024-03-31 | 413.00 Cr | 252.50 Cr | 1,357.60 Cr | 5,220.20 Cr | 3,441.90 Cr | 11,419.80 Cr | 6,914.80 Cr | 29,280.80 Cr | 7,179.20 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,170.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 1,023.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 911.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1,419.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 1,182.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-10-06 | October 06, 15 | 5:1 |
| 2010-04-05 | April 05, 10 | 3:2 |
| 2006-08-30 | August 30, 06 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,733.80 | ₹4,159,871,664,000.00 | ₹2,318,664.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,650.00 | ₹1,765,368,850,000.00 | ₹226,973.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,730.60 | ₹1,262,602,917,000.00 | ₹439,520.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,292.10 | ₹1,075,456,274,108.00 | ₹1,386,961.00 |
| Mankind Pharma Limited | MANKIND | ₹2,575.50 | ₹1,062,982,921,380.00 | ₹763,328.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.15 | ₹1,001,349,784,500.00 | ₹775,382.00 |
| Lupin Limited | LUPIN | ₹1,984.60 | ₹906,460,096,200.00 | ₹754,124.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.00 | ₹672,568,716,000.00 | ₹672,249.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,099.60 | ₹609,733,674,000.00 | ₹69,765.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,153.60 | ₹607,748,073,600.00 | ₹786,090.00 |
| Laurus Labs Limited | LAURUSLABS | ₹881.45 | ₹475,603,095,050.00 | ₹5,551,173.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,529.50 | ₹388,040,268,000.00 | ₹501,348.00 |
| Cohance Lifesciences Limited | COHANCE | ₹997.40 | ₹381,572,333,779.00 | ₹30,739.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,800.50 | ₹349,816,056,000.00 | ₹68,739.00 |
| Piramal Enterprises Limited | PEL | ₹1,287.60 | ₹291,870,592,800.00 | ₹4,377,271.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,782.60 | ₹278,652,466,800.00 | ₹198,162.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,684.80 | ₹273,744,619,200.00 | ₹253,355.00 |
| Eris Lifesciences Limited | ERIS | ₹1,816.60 | ₹247,415,470,200.00 | ₹258,998.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,340.00 | ₹233,500,000,000.00 | ₹39,783.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.60 | ₹198,056,878,800.00 | ₹43,245.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,236.30 | ₹196,919,100,300.00 | ₹1,978,762.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,910.00 | ₹178,463,909,000.00 | ₹72,265.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹973.15 | ₹174,300,896,500.00 | ₹709,365.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,145.80 | ₹163,105,905,860.00 | ₹121,630.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹492.15 | ₹119,417,244,600.00 | ₹954,418.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,631,800.00 | ₹41,877.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹919.15 | ₹89,884,505,735.00 | ₹41,687.00 |
| Strides Pharma Science Limited | STAR | ₹945.35 | ₹87,126,008,445.00 | ₹401,712.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹946.50 | ₹85,785,667,830.00 | ₹174,284.00 |
| FDC Limited | FDC | ₹484.45 | ₹78,873,304,500.00 | ₹30,593.00 |
| Suven Life Sciences Limited | SUVEN | ₹269.30 | ₹58,727,328,200.00 | ₹85,394.00 |
| Innova Captab Limited | INNOVACAP | ₹917.50 | ₹52,503,873,275.00 | ₹36,415.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹151.93 | ₹49,304,627,460.00 | ₹195,988.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹522.25 | ₹47,665,757,500.00 | ₹446,949.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.86 | ₹44,023,913,100.00 | ₹235,318.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹619.85 | ₹43,641,035,130.00 | ₹39,695.00 |
| Hikal Limited | HIKAL | ₹329.80 | ₹40,664,669,800.00 | ₹316,649.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹404.55 | ₹40,567,464,900.00 | ₹352,761.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,405.80 | ₹39,789,526,200.00 | ₹52,499.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹705.15 | ₹35,764,573,365.00 | ₹37,012.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹59.69 | ₹32,707,374,260.00 | ₹1,444,289.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹651.90 | ₹31,390,940,700.00 | ₹124,331.00 |
| Indoco Remedies Limited | INDOCO | ₹324.50 | ₹29,934,443,550.00 | ₹64,322.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹100.29 | ₹29,437,822,830.00 | ₹15,953,556.00 |
| Alembic Limited | ALEMBICLTD | ₹114.24 | ₹29,334,775,566.00 | ₹212,418.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Dhaval Narendra Soni
Gender: male
Year Born:
Chief Financial Officer
Mr. Nitinkumar Dalsukhray Parekh
Gender: male
Year Born:
Chief Operating Officer & Executive Director
Dr. Ganesh Narayan Nayak
Gender: Not Specified
Year Born: 1955
President & Chief Executive Officer of America
Mr. Punit Patel
Gender: male
Year Born:
Head of Investor Relations
Mr. Arvind Bothra
Gender: male
Year Born:
President of Parenteral Operations
Mr. Vikram Shukla
Gender: male
Year Born: 1974
President of Finance
Mr. Tushar Dhansukh Shroff
Gender: male
Year Born:
MD & Executive Director
Dr. Sharvil Pankajbhai Patel
Gender: Not Specified
Year Born: 1979
FAQs about Zydus Lifesciences Limited
Who is the CEO of the company?
The CEO is Punit Patel.
What is the current market price of the stock?
The current price is ₹995.15.
What is the 52-week price range?
The range is ₹795-1324.3.
What is the market capitalization of the company?
The market capitalization is ₹100,134.98 crores.
What is the dividend yield?
The dividend yield is 1.11%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.12.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Zydus Lifesciences Limited (ISIN: INE010B01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹100,134.98 crores and an average daily volume of 980,617 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.